Gila Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Minneapolis MN United States (2014)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2017
NCT03490786
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Gila Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

gt-001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Feeding and Eating Disorders (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1